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The results of cardiac transplantation in patients over 69 years of agereported by Blanche and associates [J Thorac Cardiovasc Surg2001;121:532-41] demonstrate that short-term survival can beachieved in a very select, small group of such patients. As theauthors have stated, the statistical comparison of this small group ofolder patients to younger recipients is problematic because the
selection process was not uniform for both groups of patients. These data do not
justify the elimination of older age as a selection criterion for cardiac transplanta-
tion, because most reports identify increased recipient age as a risk factor for
post-transplantation mortality. Expanding the upper age limit will result in a further
distortion of the current recipient demand/donor supply dilemma and will produce
an increased mortality for all patients awaiting cardiac transplantation. The article
by Blanche’s group does raise many important moral, ethical, and practical issues
related to the treatment of patients with end-stage heart disease.
The concept of an alternative list for older patients seems rational but in turn
introduces many theoretical and practical concerns. Use of marginal donor hearts for
high-risk recipients seems likely to result in reduced recipient survivals both in the
immediate post-transplantation period and in the long term. The actuarial survival
for patients after all other cardiac surgical operations is influenced by the age of the
patient, and there is no logical reason why cardiac transplantation should be
different. There are also factors associated with long-term immunosuppression in
older patients that could be expected to adversely influence survival and quality of
life.
The number of cardiac donors in this country has remained static over the past
10 years despite intense efforts at public education and the aggressive expansion of
acceptable donor criteria. Therefore, some upper age limit must be used to prevent
further increases in mortality rates for patients awaiting transplantation. Moreover,
the upper age limit used by most programs is merely a guideline for selection. Age
alone rarely disqualifies patients from consideration. Chronologic age certainly does
not strictly correlate with physiologic age in every case. The challenge for transplant
physicians is to establish objective parameters that accurately predict the recipient’s
response to the trauma of the operation and the need for lifelong immunosuppres-
sion.
The development of more specific immunosuppressive drugs and the establish-
ment of effective immune tolerance protocols have the potential of reducing the
complications associated with immunosuppression that seem to be more frequent
and severe for elderly patients. The future implementation of immunosuppressive
strategies based on pharmacogenomics may permit the customization of drug
therapy guided by the patients’ genetic profiles and would be particularly beneficial
for elderly patients.
Society must balance the issue of reducing death on the waiting list with survival
outcome after transplantation. The expansion of the donor supply with the use of
marginal hearts could reduce the chance of death for patients awaiting transplanta-
tion. If the results of marginal donor hearts used for transplantation in patients on
alternative lists are comparable with the current results with nonmarginal donor
hearts, then those hearts should be used for the lower-risk patients who are currently
dying on the regular waiting list. The reality is that for the foreseeable future the
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demand for hearts will exceed the supply from the current
donor pool even with the liberal use of marginal, high-risk
donor hearts.
Xenotransplantation, permanent mechanical support, im-
proved medical therapy, biventricular pacing, cellular trans-
plantation, and gene therapy are potential solutions to the
current donor heart shortage. Presently, permanent mechan-
ical support would seem to be the most feasible treatment
strategy for patients with end-stage heart disease refractory
to medical therapy. The results of prospective trials such as
the Randomized Evaluation of Mechanical Assistance Ther-
apy for Congestive Heart Failure (REMATCH) study may
provide the necessary guidance for the use of this therapy
for these patients.
The objective of balancing the death of patients awaiting
transplantation with maximizing post-transplantation sur-
vival may be partially achieved by matching the risk of
marginal donor heart dysfunction with the immunopatho-
physiologic function of the high-risk recipients. The United
Network for Organ Sharing (UNOS) has made a policy
decision regarding the use of pediatric-age donor hearts for
pediatric-age recipients. This policy sets a precedent for the
matching of the risks donor heart function with recipient
parameters. All transplant physicians trying to decide
whether to use a specific donor heart for a potential recipient
use this concept on a daily basis. All of the donor data and
recipient conditions are analyzed in aggregate, and a deci-
sion is rendered concerning proceeding with transplanta-
tion. The consideration of all donor hearts including the
marginal hearts for one list of recipients seems the most
reasonable paradigm. The creation of an alternate list seems
to disadvantage the patients on this list by giving them
second-rate hearts; conversely, if the hearts are acceptable,
then the standard list patients are disadvantaged by not
being given the chance for the hearts.
The definition of a “marginal” donor heart is frequently
in the eye of the beholder. Some of the donor factors
associated with this designation include female sex, age
over 45 years, dopamine support of greater than 10 g 
kg1  min1, body surface area of less than 70% of
recipient body surface area, history of drug abuse, diabetes
mellitus, cardiac arrest, anticipated graft ischemic time of
more than 210 minutes, central venous pressure of greater
than 10 mm Hg, left ventricular hypertrophy, ventricular
dysfunction, risk factors for or the presence of coronary
artery disease, and hepatitis. Recipient factors associated
with increased risk of post-transplantation mortality include
age over 50 years, pulmonary vascular resistance of more
than 2.5 Wood units, male sex with a body surface area over
2.5 m2, more than one previous sternotomy, obesity, diabe-
tes mellitus, peripheral vascular disease, diverticulosis, and
a history of malignancy. The challenge to match donor and
recipient risks will continue until more definitive data are
available to guide the decision about which heart should be
given to which recipient. On the basis of these observations,
I would continue to advocate responsible stewardship of the
limited donor resources and select the best candidates for
transplantation irrespective of patient age. The concept of
establishing an alternative list should not be widely adopted
unless more convincing data are provided to support this
complex paradigm.
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